Dasgupta Nabarun, Brown John R, Nocera Maryalice, Lazard Allison, Slavova Svetla, Freeman Patricia R
UNC CB 7505, 725 Martin Luther King Jr. Blvd., Chapel Hill, NC, 27599, USA.
Pain Ther. 2022 Mar;11(1):133-151. doi: 10.1007/s40122-021-00343-z. Epub 2021 Dec 6.
Evaluate beliefs and behaviors pertaining to abuse-deterrent opioids (ADFs).
Survey in 2019 by invitation to all licensed physicians.
Commonwealth of Kentucky.
374 physicians.
Descriptive statistics, and hypothesis test that early adopter prescribers would have greater endorsement of opioid risk management.
Of all prescribers, 55% believed all opioid analgesics should have ADF requirements (15% were unsure); 74% supported mandating insurance coverage. Only one-third considered whether an opioid was ADF when prescribing, motivated by patient family diversion (94%) and societal supply reduction (88%). About half believed ADFs were equally effective in preventing abuse by intact swallowing, injection, chewing, snorting, smoking routes. Only 4% of OxyContin prescribers chose it primarily because of ADF properties. Instead, the most common reason (33%) was being started by another prescriber. A quarter of physicians chose not to prescribe ADFs because of heroin switching potential. Early adopters strongly believed ADFs were effective in reducing abuse (PR 3.2; 95% CI 1.5, 6.6) compared to mainstream physicians. Early-adopter risk-management practices more often included tools increasing agency and measurement: urine drug screens (PR 2.0; 1.3, 3.1), risk screening (PR 1.3; 0.94, 1.9). While nearly all respondents (96%) felt that opioid abuse was a problem in the community, only 57% believed it was a problem among patients in their practice. Attribution theory revealed an externalization of opioid abuse problems that deflected blame from patients on to family members.
The primary motivator for prescribing ADFs was preventing diversion by family members, not patient-level abuse concerns.
评估与阿片类药物滥用威慑制剂(ADF)相关的观念和行为。
2019年对所有持照医生进行邀请式调查。
肯塔基州。
374名医生。
描述性统计,以及关于早期采用者处方医生对阿片类药物风险管理认可度更高的假设检验。
在所有处方医生中,55%认为所有阿片类镇痛药都应具备ADF要求(15%不确定);74%支持强制保险覆盖。只有三分之一的人在开处方时会考虑一种阿片类药物是否为ADF,其动机来自患者家庭药物转移(94%)和社会供应减少(88%)。约一半的人认为ADF在通过完整吞咽、注射、咀嚼、吸食、吸烟途径预防滥用方面效果相同。只有4%的奥施康定处方医生主要因其ADF特性而选择它。相反,最常见的原因(33%)是由另一位处方医生开始使用。四分之一的医生因海洛因转换可能性而选择不开具ADF。与主流医生相比,早期采用者坚信ADF在减少滥用方面有效(相对危险度3.2;95%置信区间1.5,6.6)。早期采用者的风险管理做法更多地包括增加自主性和衡量的工具:尿液药物筛查(相对危险度2.0;1.3,3.1)、风险筛查(相对危险度1.3;0.94,1.9)。虽然几乎所有受访者(96%)都认为阿片类药物滥用是社区问题,但只有57%认为这是他们执业中患者的问题。归因理论揭示了阿片类药物滥用问题的外部化,即将责任从患者转移到家庭成员身上。
开具ADF的主要动机是防止家庭成员转移药物,而非患者层面的滥用担忧。